RxDoctor Payments Data

Mikayla Semenko

Physician Assistant · Reno, NVNPI 1053071100

Payments from drug & device makers

$721in general payments, 2019–2025

Across 25 payments — averaging $28.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$171
  • Amgen$123
  • Gilead$122
  • Corcept Therapeutics$77
  • Dexcom, Inc.$49
  • Lilly USA, LLC$47
  • plus $132 from 5 others

What the payments were for

  • Food & beverage$721100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$721 in reported general payments places this provider in the 60th percentile of 881 physician assistant providers in Nevada.

See all physician assistant providers in Nevada

Medicare billing

Part B allowed, 2024
$273
Medicare patients
13
Services billed
45

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide32$42,494
SynjardyEmpagliflozin/Metformin Hcl30$26,122
Trelegy ElliptaFluticasone/Umeclidin/Vilanter28$20,111
JardianceEmpagliflozin15$15,229
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate15$3,640
Albuterol Sulfate HfaAlbuterol Sulfate24$1,214
Rosuvastatin Calcium41$1,013
Gabapentin34$409
Venlafaxine Hcl ErVenlafaxine Hcl12$385
Omeprazole29$351
Metoprolol Succinate14$321
Losartan Potassium33$302
Duloxetine Hcl13$288
Ibuprofen25$267
Escitalopram Oxalate13$253

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$47$42,49432 claims
Boehringer IngelheimSynjardy, Jardiance$41$41,35145 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 881 physician assistant providers in Nevada.

Other physician assistant in Reno

See the full list for Nevada

Where these figures come from

Is this you, or does something look wrong? →